Geron mit Hammernews!! (Seite 61)
eröffnet am 18.03.03 18:26:10 von
neuester Beitrag 21.03.24 13:47:21 von
neuester Beitrag 21.03.24 13:47:21 von
Beiträge: 3.090
ID: 709.348
ID: 709.348
Aufrufe heute: 3
Gesamt: 213.090
Gesamt: 213.090
Aktive User: 0
ISIN: US3741631036 · WKN: 902213 · Symbol: GON
3,7410
EUR
+1,71 %
+0,0630 EUR
Letzter Kurs 11:24:52 Tradegate
Neuigkeiten
02.05.24 · Business Wire (engl.)  |
25.04.24 · Business Wire (engl.) |
18.04.24 · Business Wire (engl.) |
03.04.24 · Business Wire (engl.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7850 | +42,80 | |
| 1,6600 | +32,80 | |
| 5,8700 | +26,24 | |
| 5,5500 | +26,14 | |
| 3,6500 | +21,26 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 6,4500 | -33,85 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,8800 | -44,05 |
Beitrag zu dieser Diskussion schreiben
Feedback
Ja, weiter abwärts, vielleicht knallen sie sie auf unter 1 €, dann bin ich dabei ! Gruß B.
hmmh steht fast wieder da, wo sie vor einem Jahr stand !!! Einstieg, vor allem wegen Phase 2/3 Jonson.... ?? Gruß B.
Könnte was dran sein. Kenn mich leider ind iesem Segment nicht aus !! Aber ein paar hundert € könnte man durchaus riskieren.... hmmmh, mal sehn. Gruß B.
Und sie steigt und steigt. Seit 1,2 auf der Watchlist aber leider nicht reingegangen, war mir zu undurchsichtig.
Wann bekommen die denn weitere Zahlungen von J&J und was haben die jetzt mit dem Geld vor wenns das letzte MED in der Pipeline war?
Trading Spotlight
Mal wieder eine Aktie die hier fast keiner kennt.
Das ging schnell mit den 3,50 hätte ich nicht gedacht, warum aber hier in Deutschland kaum einer zugreift verstehe ich nicht aber egal bei 4,51 Euro ist erst die nächste Hürde mal schauen.
Geiles Teil auf jeden
Geiles Teil auf jeden
Nicht schlecht erstes Ziel 3,50 Dollar und dann wie damals, es sah noch nie so gut aus.
GERON SELLS LAST DRUG IN PIPELINE TO J&J UNIT GERN.O JNJ.N - RTRS
14-Nov-2014 00:27
Nov 13 (Reuters) - Geron Corp GERN.O licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson JNJ.N for up to $935 million, sending its shares up as much as 33 percent in extended trading.
The license deal comes as a welcome break to the company, which has seen its stock price drop from a high of $71.69 in 2000 to $2.31 on Thursday.
The drug developer will receive $35 million in upfront payment and the rest in milestone payments. (Full Story)
Under the deal, J&J's unit Janssen Biotech Inc, will be responsible for the development, regulatory approval and sales of the cancer compound, imetelstat, worldwide. Geron will receive royalties on net sales.
If successful, imetelstat would compete with Incyte Corp's INCY.O myelofibrosis drug, Jakafi, which generated sales of $235.4 million last year.
Some analysts have indicated that imetelstat's ability to evoke a disease-modifying effect - defined as partial or complete remission - suggests it would be superior to Jakafi.
Geron did not disclose plans for its pipeline. The company could not be reached immediately for additional comments.
The deal includes a clause for Janssen to terminate the agreement at any time due to a safety-related concern, according to a filing. (http://1.usa.gov/1zRPRsJ)
The Menlo Park, California-based company came under pressure in March after the U.S. Food and Drug Administration placed a hold on Geron's studies of the drug in blood cancers, citing possible liver damage. (Full Story)
Once heralded as a pioneer in stem-cell technology, Geron focused its research and development on imetelstat in blood cancers from December 2012 when it stopped development of its brain cancer drug and cut about 40 percent of its workforce.
The company had to abandon its research in human embryonic stem cells in November 2011 when political and general sentiment were against such testing, a move that left the company with two cancer compounds and a portfolio of stem cell therapies.
In October last year, the company completed the sale of its stem cell assets to BioTime.
Geron's shares have fallen 67 percent since it sold its stem cell assets.
14-Nov-2014 00:27
Nov 13 (Reuters) - Geron Corp GERN.O licensed its cancer compound, the last in its pipeline, to a unit of Johnson & Johnson JNJ.N for up to $935 million, sending its shares up as much as 33 percent in extended trading.
The license deal comes as a welcome break to the company, which has seen its stock price drop from a high of $71.69 in 2000 to $2.31 on Thursday.
The drug developer will receive $35 million in upfront payment and the rest in milestone payments. (Full Story)
Under the deal, J&J's unit Janssen Biotech Inc, will be responsible for the development, regulatory approval and sales of the cancer compound, imetelstat, worldwide. Geron will receive royalties on net sales.
If successful, imetelstat would compete with Incyte Corp's INCY.O myelofibrosis drug, Jakafi, which generated sales of $235.4 million last year.
Some analysts have indicated that imetelstat's ability to evoke a disease-modifying effect - defined as partial or complete remission - suggests it would be superior to Jakafi.
Geron did not disclose plans for its pipeline. The company could not be reached immediately for additional comments.
The deal includes a clause for Janssen to terminate the agreement at any time due to a safety-related concern, according to a filing. (http://1.usa.gov/1zRPRsJ)
The Menlo Park, California-based company came under pressure in March after the U.S. Food and Drug Administration placed a hold on Geron's studies of the drug in blood cancers, citing possible liver damage. (Full Story)
Once heralded as a pioneer in stem-cell technology, Geron focused its research and development on imetelstat in blood cancers from December 2012 when it stopped development of its brain cancer drug and cut about 40 percent of its workforce.
The company had to abandon its research in human embryonic stem cells in November 2011 when political and general sentiment were against such testing, a move that left the company with two cancer compounds and a portfolio of stem cell therapies.
In October last year, the company completed the sale of its stem cell assets to BioTime.
Geron's shares have fallen 67 percent since it sold its stem cell assets.
GERON CORP UP 44.2 PCT IN PREMARKET; LICENSED CANCER COMPOUND TO JOHNSON & JOHNSON UNIT FOR UP TO $935 MLN GERN.O - RTRS
Durchsuchen
